Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
Charu Aggarwal, Hossein BorghaeiDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Lung cancer is the leading cause of mortality in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most NSCLC patients prese...
Main Authors: | Charu Aggarwal, Hossein Borghaei |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-08-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/rational-use-of-cetuximab-in-the-treatment-of-advanced-non-small-cell--a3493 |
Similar Items
-
Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer
by: Sheng YANG, et al.
Published: (2016-05-01) -
Cetuximab and biomarkers in non-small-cell lung carcinoma
by: Patil N, et al.
Published: (2012-07-01) -
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
by: Vadakara J, et al.
Published: (2012-09-01) -
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
by: Chad A Reade, et al.
Published: (2009-05-01) -
Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-small Cell Lung Cancer Cell lines
by: Zhen CHEN, et al.
Published: (2010-08-01)